Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators..

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
2.

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.

Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S; AVERROES Steering Committee and Investigators..

Lancet Neurol. 2012 Mar;11(3):225-31. doi: 10.1016/S1474-4422(12)70017-0.

PMID:
22305462
3.

Apixaban in patients with atrial fibrillation.

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators..

N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432.

4.

Sustained benefits of a health project for middle-aged football supporters, at Glasgow Celtic and Glasgow Rangers Football Clubs.

Brady AJ, Perry C, Murdoch DL, McKay G.

Eur Heart J. 2010 Dec;31(24):2966-8. No abstract available.

5.

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators..

Lancet. 2009 Nov 28;374(9704):1840-8. doi: 10.1016/S0140-6736(09)61913-9. Erratum in: Lancet. 2009 Dec 5;374(9705):1888.

PMID:
19922995
6.

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.

Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators..

Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1.

PMID:
19082699
7.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators., Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Erratum in: Lancet. 2008 Oct 18;372(9647):1384.

PMID:
18757085
8.

Validity of self-reported smoking status: Comparison of patients admitted to hospital with acute coronary syndrome and the general population.

Pell JP, Haw SJ, Cobbe SM, Newby DE, Pell AC, Oldroyd KG, Murdoch DL, Pringle SD, Dunn FG, Macintyre PD, Gilbert TJ, Fischbacher CM, Borland W.

Nicotine Tob Res. 2008 May;10(5):861-6. doi: 10.1080/14622200802023858.

PMID:
18569760
9.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators., Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317.

10.

The complex nature of informal care in home-based heart failure management.

Clark AM, Reid ME, Morrison CE, Capewell S, Murdoch DL, McMurray JJ.

J Adv Nurs. 2008 Feb;61(4):373-83. doi: 10.1111/j.1365-2648.2007.04527.x.

PMID:
18234035
11.

Are atrial fibrillation guidelines altering management? A community based study.

Murdoch DL, O'Neill K, Jackson J, McMahon A, Rumley A, Wallace I, Lowe GD, Tait RC.

Scott Med J. 2005 Nov;50(4):166-9.

PMID:
16374981
12.

A qualitative study of the contribution of pharmacists to heart failure management in Scotland.

Clark AM, McMurray JJ, Morrison CE, Murdoch DL, Capewell S, Reid ME.

Pharm World Sci. 2005 Dec;27(6):453-8.

PMID:
16341953
13.

Patients strategies for managing medication for chronic heart failure.

Reid M, Clark A, Murdoch DL, Morrison C, Capewell S, McMurray J.

Int J Cardiol. 2006 Apr 28;109(1):66-73.

PMID:
15993960
14.

Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.

Murdoch DL, Goa K, Figgitt DP.

Drugs. 2003;63(23):2625-49. Review.

PMID:
14636084
15.

The value of routine non-invasive tests to predict clinical outcome in stable angina.

Daly C, Norrie J, Murdoch DL, Ford I, Dargie HJ, Fox K; TIBET (Total Ischaemic Burden European Trial) study group..

Eur Heart J. 2003 Mar;24(6):532-40.

16.
17.

Acute effects of cicletanine in angina pectoris.

Murdoch DL, Henderson E, Dargie HJ, McInnes GT.

Eur J Clin Pharmacol. 1993;44(1):89-91.

PMID:
8436163
18.

Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Murdoch DL, Thomson GD, Thompson GG, Murray GD, Brodie MJ, McInnes GT.

Br J Clin Pharmacol. 1991 Mar;31(3):323-32.

19.

Twice-daily low-dose captopril in diuretic-treated hypertensives.

Murdoch DL, Gillen GJ, Morton JJ, Leckie B, Murray GD, Davies DL, McInnes GT.

J Hum Hypertens. 1989 Feb;3(1):29-33.

PMID:
2657056
20.
Items per page

Supplemental Content

Loading ...
Support Center